Wetenschappelijk onderzoek

Dr. Cornel E.B en mw dr. J.l.J. Vriesema hebben hun bijdrage geleverd aan onderzoek met betrekking tot de diagnostiek en behandeling van blaaskanker. Zo ook Mw Dr. P.J.M. Moonen. Zij is sinds augustus 2013 werkzaam als uroloog en chef de clinique binnen ZGT. Hieronder vindt u een overzicht van de verschillende publicaties en links naar de samenvattingen.        

Publicaties

Van der Heijden AG, Moonen PMJ, Cornel EB, Vergunst H, de Reijke TM, van Boven E, Barten EJ, Puri R, van KaLken CK and Witjes JA

Phase II Marker Lesion Study With Intravesical Instillation of Apaziquone for Superficial Bladder Cancer: Toxicity and Marker Response. J.Urol. 2006 Oct;176(4):1349-53.

 

Cornel E.B, Oosterwijk E., Kiemeney L.A.

The effect on pain experience for male patients of watching  their own office based flexible cystoscopy. BJU Int. 2008 Nov;102(10):1445-6.

 

Lambertus A Kiemeney, Steinunn Thorlacius, Patrick Sulem, Frank Geller, Katja K H Aben,Simon N Stacey, Julius Gudmundsson, Margret Jakobsdottir, Jon T Bergthorsson, Asgeir Sigurdsson, Thorarinn Blondal, J Alfred Witjes, Sita H Vermeulen, Christina A Hulsbergen-van de Kaa, Dorine W Swinkels, Martine Ploeg, Cornel EB, Henk Vergunst, Thorgeir E Thorgeirsson, Daniel Gudbjartsson, Sigurjon A Gudjonsson, Gudmar Thorleifsson, Kari T Kristinsson, Magali Mouy, Steinunn Snorradottir, Donatella Placidi, Marcello Campagna, Cecilia Arici, Kvetoslava Koppova, Eugene Gurzau, Peter Rudnai, Eliane Kellen, Silvia Polidoro, Simonetta Guarrera, Carlotta Sacerdote, Manuel Sanchez, Berta Saez, Gabriel Valdivia, Charlotta Ryk, Petra de Verdier, Annika Lindblom, Klaus Golka, D Timothy Bishop, Margaret A Knowles, Sigfus Nikulasson, Vigdis Petursdottir, Eirikur Jonsson, Gudmundur Geirsson, Baldvin Kristjansson, Jose I Mayordomo, Gunnar Steineck, Stefano Porru, Frank Buntinx, Maurice P Zeegers, Tony Fletcher, Rajiv Kumar, Giuseppe Matullo, Paolo Vineis, Anne E Kiltie, Jeffrey R Gulcher, Unnur Thorsteinsdottir, Augustine Kong, Thorunn Rafnar & Kari Stefansson.

Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet. 2008 Nov;40(11):1307-12.

 

Marieke J.H. Coenen, Martine Ploeg, Mascha M.V.A.P. Schijvenaars,

Allelic imbalance analysis using a single nucleotide polymorphism microarray for the detection of bladder cancer recurrence. Clin Cancer Res. 2008 Dec 15;14(24):8198-204.

 

Hendricksen K, van der Heijden AG, Cornel E.B, Vergunst H, de Reijke TM, van Boven E, Smits GA, Puri R, Gruijs S, Witjes JA.

Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer. World J Urol. 2009 Jun;27(3):337-42.

Cornel E.B

Letter to the Editor of British Journal Urology Concerning: Surgery illustrated- surgical atlas Transurethral resection of bladder tumours. BJU int 2010 Oct;106(8):1237.

 

K. Hendricksen, Cornel E.B, T.M. de Reijke, H.C. Arentsen, S. Chawla, J.A. Witjes.

Phase 2 study of adjuvant intravesical instillations of apaziquone in high-risk non-muscle invasive bladder cancer J Urol. 2012 April;187:1195.


Falke J, Lammers RJ, Arentsen HC, Ravic M, Pozzi R, Cornel E.B, Vergunst H, de Reijke TM, Witjes JA.

Results of a phase 1 dose escalation study of intravesical TMX-101 in patients with non-muscle invasive bladder cancer.J Urol. 2012 Nov 30. doi:pii: S0022-5347(12)05771-0. 10.1016/j.juro.2012.11.150. [Epub ahead of print].

 

Span PN, Witjes JA, Grebenchtchikov N, Geurts-Moespot A, Moonen PM, Aalders TW, Vriesema JL, Kiemeney LA, Schalken JA, Sweep FC.
Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison between normal and matched cancerous tissues. BJU Int. 2008 Jul;102(2):177-82. doi: 10.1111/j.1464-410X.2008.07568.x. Epub 2008 Jul 1.

 

Schrier BP, Vriesema JL, Witjes JA, Kiemeney LA, Schalken JA. 
The predictive value of p53, p27(kip1), and alpha-catenin for progression in superficial bladder carcinoma. Eur Urol. 2006 Jul;50(1):76-82. Epub 2006 Jan 6. 

 

Heesakkers JP, Vriesema JL 

The role of urodynamics in the treatment of lower urinary tract symptoms in women. Curr Opin Urol. 2005 Jul;15(4):215-21.

 

Witjes JA, van der Heijden AG, Vriesema JL, Peters GJ, Laan A, Schalken JA. 
Intravesical gemcitabine: a phase 1 and pharmacokinetic study. Eur Urol. 2004 Feb;45(2):182-6. 

 

Witjes JA, Vriesema JL, Brinkman K, Bootsma G, Barentsz JO.  
Mycotic aneurysm of the popliteal artery as a complication of intravesical BCG therapy for superficial bladder cancer. Case report and literature review. Urol Int. 2003;71(4):430-2.

 

Witjes JA, Vriesema JL, van der Heijden AG, Peters GJ, Schalken JA. 
Pharmacokinetics of intravesical gemcitabine: a preclinical study in pigs. Eur Urol. 2003 Nov;44(5):615-9. 

 

Vriesema JL, Atsma F, Kiemeney LA, Peelen WP, Witjes JA, Schalken JA. 
Diagnostic efficacy of the ImmunoCyt test to detect superficial bladder cancer recurrence. Urology. 2001 Sep;58(3):367-71.

 

Vriesema JL, Aben KK, Witjes JA, Kiemeney LA, Schalken JA. 
Superficial and metachronous invasive bladder carcinomas are clonally related. Int J Cancer. 2001 Sep 1;93(5):699-702.

 

Vriesema JL, Poucki MH, Kiemeney LA, Witjes JA. 
Patient opinion of urinary tests versus flexible urethrocystoscopy in follow-up examination for superficial bladder cancer: a utility analysis. Urology. 2000 Nov 1;56(5):793-7.

 

Mungan NA, Vriesema JL, Thomas CM, Kiemeney LA, Witjes JA. 
Urinary bladder cancer test: a new urinary tumor marker in the follow-up of superficial bladder cancer. Urology. 2000 Nov 1;56(5):787-92.

 

Vriesema JL, van der Poel HG, Debruyne FM, Schalken JA, Kok LP, Boon ME. 
Neural network-based digitized cell image diagnosis of bladder wash cytology. Diagn Cytopathol. 2000 Sep;23(3):171-9.

 

PN Span, JA Witjes, N. Grebenchtchikov, A. Geurts-Moespot, Moonen PMJ, TW Aalders-Hulscher, Vriesema JL, LALM Kiemeney, JA Schalken, FCGJ Sweep.

Components in the plasminogen activator system and their complexes in renal cell and bladder cancer; comparison between normal and matched cancerous tissues. BJU International November 2007. 

 

Moonen PMJ, JA Witjes.

Using FISH in detecting bladder cancer. Hospital Healthcare Europe 2006/07 (HHE). Herfst 2006.

 

Moonen PMJ, GFM Merkx, P Peelen, HFM Karthaus, DFCM Smeets, JA Witjes.

UroVysion® compared to cytology and quantitative cytology in the surveillance of non-musle “invasive” bladder cancer. Eur. Urol. 2007 May: 51(5):1275-1280. 

 

Hendricksen K, Moonen PMJ, van der Heijden AG, Molkenboer-Kuenen J, Hulsbergen-van de Kaa, Witjes JA.

Intravesical Pemetrexed: potential and toxicity in a pre-clinical pig study. Clinical Cancer Research 2006 6;12 (8) April 15, 2006. 2597-2601 

 

Witjes JA, Moonen PMJ, Van der Heijden AG.

Review pathology in a diagnostic bladder cancer trial: the impact of patient risk category. Urology Vol 67 (4) april 2006, 751-755. 

 

Moonen PMJ, JM Bakkers, LALM Kiemeney, JA Schalken, WJ Melchers, JA Witjes.

Human Papilloma Virus DNA an p53 mutation analysis in relation to clinical outcome of bladder cancer. Eur. Urol. 2006 Nov 15. 

 

Moonen PMJ, B.van Balken-Ory, LALM Kiemeney, JA Schalken, JA Witjes.

Prognostic value p53 in high risk superficial bladder cancer with long term follow-up. J. Urol. 2007 Jan; 177 (1):80-3. 

 

Witjes JA, Moonen PMJ, Van der Heijden AG.

Review pathology in a diagnostic bladder cancer trial: the impact of patient risk category. Eur. Urol. Suppl. 2006 April Vol 5 (2) Abstract 459. 

 

Hendricksen K, Moonen PMJ, van der HeijdenAG, Molkenboer-Kuenen J, Hulsbergen-van de Kaa, Witjes JA.

Intravesical Pemetrexed: potential and toxicity in a pre-clinical pig study. Eur. Urol. Suppl. 2006 April Vol 5 (2) , Abstract 662. 

 

Van der Heijden AG, Moonen PMJ, Cornel EB Vergunst H, De Reijke TM, Van Boven E, Barten EJ, Puri R, Chawla S, Lenaz G, Witjes JA.

Phase II marker lesion study with intravesical instillation of Eoquin TM in superficial bladder cancer, toxicity and marker respons- the final results. Eur. Urol. Suppl. 2006 April Vol 5 (2), Abstract 664. 

 

Moonen PMJ, GFM Merkx, DFCM Smeets, JA Witjes.

UroVysion: een multipele FISH analyse in de follow-up van het oppervlakkig blaascarcinoom. Abstract 5, NTVU no 2 april 2006. 

 

Moonen PMJ, B. van Balken-Ory, LALM Kiemeney, JA Schalken, JA Witjes.

De prognostische waarde van p53 voor het hoog-risico oppervlakkig blaascarcinoom met een lange follow-up. Abstract 3, NTVU, no.2 april 2006. 

 

PMJ Moonen, P.Peelen, LALM Kiemeney, ME Boon, JA Schalken, JA Witjes.

Quantitative cytology on bladder wash versus voided urine: a comparison of results. Eur. Urol. 2006 June: 49(6): 1044-1050.

 

Moonen PMJ, JA Witjes.

Diagnosis of bladder cancer: fluorescence cystoscopy and urinary markers. Business Briefing: European Kidney and Urological Disease 2006: pp. 76-79.

 

Moonen PMJ, J.A.Witjes.

Chapter 25: Risk Stratification of Ta, Tis, T1 Cancer. Bladder Cancer Textbook Dec. 2005. 

 

Antoine G. van der Heijden1, Moonen PMJ1, Cornel E.B2, Henk Vergunst3, Theo M. de Reijke4, Erika van Boven5, Evert J. Barten6, Rajiv Puri7, Coenraad K. van Kalken8, J. Alfred Witjes1.

Phase II marker lesion study with intravesical instillation of EOquinTM in superficial bladder cancer – toxicity and marker respons. Journal of Urology Vol 176 (4): pp 1349-1353. 

 

K. Hendricksen, Moonen PMJ, AG van der Heijden, JA Witjes.

False-positive lesions detected by fluorescence cystoscopie: any association with early malignant genetic changes? World Journal of Urology 24, 597 - 601.

 

Moonen PMJ, L.A.L.M. Kiemeney, J.A. Witjes.

Urinary NMP22® BladderChek® test in the diagnosis of superficial bladder cancer. Eur. Urol. 2005 Dec: 48 (6): 951-956. 

 

Van der Heijden A., Moonen PMJ, De Reijke T., Van Boven E., Vergunst H., Barten E., Cornel EB, Lenaz G., Chawla S., Witjes J.A.

Phase 2 marker lesion study with intravesical instillation of EOquinTM in superficial bladder cancer – preliminary results of the marker respons. Eur. Urol. Suppl. 2005 4(3): 221 abstract 873. 

 

Van der Heijden A., Moonen PMJ, Verhaegh G., Jansen C., Schalken J., Witjes J.A.

Effect of hyperthermia on the cytotoxicicity of four chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder – an invitro study. Eur. Urol. Suppl. 2005 Mar 4 (3): 120 abstract 472. 

 

Witjes J.A., Moonen PMJ, Van der Heijden A., Susani M., Bostwick D., Knuchel R.

Superficial bladder cancer risk category and the impact of review pathology. Eur. Urol. Suppl. 2005 Mar; 4(3):37 abstract 137. 

 

A.G. van der Heijden, Moonen PMJ, T.M. de Reijke, E.van Boven, H.Vergunst, E.J. Barten, Cornel EB, J.A. Witjes.

Fase 2 marker-laesie studie met intravesicale EOquin® spoelingen bij oppervlakkig blaascarcinoom: voorlopige resultaten van de marker-respons. Abstract, NTVU nr. 2 maart 2005. 

 

Witjes JA, Moonen PMJ, van der Heijden AG.

Comparison of hexaminolevulinate based flexible and rigid fluorescence cystoscopy with rigid white light cystoscopy. Results of a prospective Phase II study. Eur Urol. 2005 Mar;47(3):319-22.

 

Moonen PMJ, J.A.Witjes.

The Golden standard and six non-invasive methods for diagnosis and follow-up of superficial bladder cancer : A practical overview. Uro Vol.8 No.2: 2003.